Understanding the genetics and risk factors for esophageal adenocarcinoma
Genetics, Epigenetics, and Risk Prediction for Esophageal Adenocarcinoma
This study is looking at the genes and other factors that might help us understand why some people with Barrett's esophagus develop esophageal adenocarcinoma, a serious type of cancer, so we can better identify those at higher risk and improve how we monitor them without putting everyone through unnecessary tests.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10914882 on NIH RePORTER |
What this research studies
This research investigates the genetic and epigenetic factors that contribute to the development of esophageal adenocarcinoma (EAC), a highly lethal cancer. It aims to identify individuals with Barrett's esophagus, a precursor to EAC, who are at high risk of progression to cancer. By utilizing biomarker-assisted risk stratification, the study seeks to improve screening and surveillance strategies, ultimately reducing unnecessary procedures for those unlikely to progress. The research employs genome-wide association studies and explores the role of the epigenome in cancer development.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Barrett's esophagus, particularly those with a history of gastroesophageal reflux disease or obesity.
Not a fit: Patients without Barrett's esophagus or those who do not have risk factors for esophageal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better screening methods and personalized surveillance for patients at risk of esophageal adenocarcinoma.
How similar studies have performed: Previous research has shown promise in identifying genetic markers associated with cancer risk, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Kooperberg, Charles L — Fred Hutchinson Cancer Center
- Study coordinator: Kooperberg, Charles L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.